Congenital Ichthyosiform Erythroderma

BRANFORD, Conn.--(BUSINESS WIRE)-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights Completed an initial public offering, raising $7.5 million in gross proceeds. Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Completed and filed post-IND, FDA commitments for characterization of drug substance and drug product for ATR-12. Selected and hired clinical research organization for ATR-12 clinical trial and selected initial clinical sites for activation. Advanced ATR-04 into IND-enabling studies. Advanced Bayer Joint Development Agreement and discussions with Bayer for a license agreement. Strengthened IP portfolio with U.S. patent issuance from the USPTO for treating skin diseases with recombinant microorganisms, including ichthyosis vulgaris, a condition affecting about 1.3 million Americans. Named Travis Whitfill COO and added Barbara Ryan and John Schroer to board of directors. Successfully completed a follow-on public offering in February 2024, raising $5.0 million in gross proceeds. “Throughout 2023 and now into 2024, Azitra's unwavering commitment to combatting multiple serious skin conditions and diseases has propelled the company towards fundamental near-term catalysts,” said Francisco Salva, CEO of Azitra. “For our leading program, ATR-12 targeting Netherton’s syndrome, we've transitioned into the operational phase for our Phase 1b clinical trial. With a CRO onboard and discussions finalized with lead sites to activate the program and recruit ~12 patients, we're poised to execute on a series of potentially high-impact catalysts. Moving forward, we're focused on executing on key value-driving milestones, including getting the first patient enrolled, and a release of initial clinical data.” “Next, for our ATR-04 program targeting EGFRi-associated rash, we intend to submit an IND for a Phase 1b clinical trial in cancer patients undergoing EGFRi targeted therapy in mid-2024. Subject to FDA clearance of our IND, we plan to initiate a Phase 1b clinical trial by year end. “Additionally, regarding our Joint Development Agreement with Bayer, we are pleased with the recent progress of our collaboration and Bayer’s re-affirmed commitment to an execution of a license agreement.” Pipeline and Upcoming Milestones ATR-12 - Netherton syndrome (Rare skin disease with no FDA approved treatment options). Global Prevalence: 20K+ patients. Estimated Peak Sales Opportunity: ~$250 million. Clinical Status: Phase 1b Upcoming milestones: First patient dosed in 12-patient clinical trial Publication of preclinical data at major medical meetings in Q2 2024 Initial clinical safety data in late 2024 ATR-04 - EGFRi-associated rash (Chemotherapy agents such as EGFR inhibitors and immunotherapies such as early BTK inhibitors lead to an aggressive and debilitating rash on many patients). US Prevalence: ~150K patients. Estimated Peak Sales Opportunity: >$1B. Clinical Status: Pre-IND Upcoming milestones: Publication of preclinical data at major medical meetings in Q2 2024 IND submission in mid-2024 First patient dosed in first-in-human clinical trial in late 2024 or early 2025 Bayer Joint Development Agreement (Joint development on S. epidermidis strains and products for eczema-prone skin.) Global Prevalence: 230 million. Annual economic burden in Europe: $30B. Status: Azitra is responsible for early research, and Bayer is responsible for clinical development and commercialization Upcoming milestones: Execution of a licensing agreement with upfront payment Financial Results for the Year Ended December 31, 2023 Service Revenue – Related Party: The Company generated $0.7 million of service revenue during the year ended December 31, 2023, compared to $0.3 million for the comparable period in 2022. Research and Development (R&D) expenses: R&D expenses for the year ended December 31, 2023, were $3.8 million compared to $6.1 million for the comparable period in 2022. General and Administrative (G&A) expenses: G&A expenses for the year ended December 31, 2023, were $4.5 million compared to $3.6 million for the comparable period in 2022. Net Loss was $11.3 million for the year ended December 31, 2023, compared to $10.7 million for the comparable period in 2022. Cash and cash equivalents: As of December 31, 2023, the Company had cash and cash equivalents of $1.8 million, which does not include net proceeds of approximately $4.4 million from a February 15, 2024, follow-on offering. About Azitra, Inc. Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies. Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described in its registration statement on Form S-1, which is on the SEC, and in its most recent annual report on Form 10-K to be filed with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Condensed Consolidated Statement of Operations Audited 2023 2022 Service revenue – related party $ 686,000 $ 284,000 Total revenue 686,000 284,000 Operating expenses: General and administrative 4,493,332 3,639,666 Research and development 3,809,063 6,097,938 Total operating expenses 8,302,395 9,737,604 Loss from operations (7,616,395 ) (9,453,604 ) Non- operating income (expense): Interest income 1,577 4,818 Interest expense (167,726 ) (251,891 ) Employee retention credit - 229,813 Other income - 65,849 Forgiveness of accounts payable 56,285 - Change in fair value of convertible note (3,630,100 ) (1,250,000 ) Other income (expense) 89,886 (25,351 ) Total non-operating expenses (3,650,078 ) (1,226,762 ) Loss before income taxes (11,266,473 ) (10,680,366 ) Income tax benefit (expense) (17,308 ) - Net loss $ (11,283,781 ) (10,680,366 ) Dividends on preferred stock (1,355,347 ) (2,768,984 ) Net loss attributable to common shareholders $ (12,639,128 ) (13,449,350 ) Net loss per Share, basic and diluted (1.83 ) (12.74 ) Weighted average common stock outstanding, basic and diluted $ 6,924,453 $ 1,055,399 Condensed Consolidated Balance Sheets Audited December 31, December 31, 2023 2022 Assets Current Assets: Cash and cash equivalents $ 1,795,989 $ 3,492,656 Other receivables 223,474 266,208 Prepaid expenses and other current assets 516,116 377,019 Total current assets $ 2,535,579 $ 4,135,883 Property and equipment, net 710,075 846,958 Other assets 1,869,832 2,184,602 Total assets $ 5,115,486 $ 7,167,443 Liabilities, preferred stock, and stockholders’ equity Current liabilities: Accounts payable $ 897,272 $ 784,687 Current financing lease liability 14,600 - Current operating lease liability 307,655 287,384 Accrued expenses 383,668 993,961 Contract liabilities - 156,000 Total current liabilities 1,603,195 2,222,032 Long-term financing lease liability 26,169 - Long-term operating lease liability 537,523 840,896 Warrant liability 35,453 70,283 Convertible notes payable, net 0 6,600,000 Total liabilities 2,202,340 9,733,211 Stockholders’ equity (deficit) Preferred stock 0 33,694,542 Common stock 1,210 104 Additional paid-in capital 51,510,269 1,054,138 Accumulated deficit (48,598,333 ) (37,314,552 ) Total stockholders’ equity (deficit) 2,913,146 (36,260,310 ) Total liabilities, preferred stock and stockholders’ equity (deficit) $ 5,115,486 $ 7,167,443

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen years and older No safety concerns have been observed to date in either ongoing clinical study Quoin expects its cash runway will extend into the second half of 2025 following $6.5 million offering on March 5th Cash Runway to be further extended by $8 million Equity Line of Credit arrangement signed January 25, 2024 ASHBURN, Va., March 13, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023. Quoin CEO, Dr. Michael Myers, said, “2023 marked another year of significant progress for Quoin and for the development of QRX003 for the treatment of Netherton Syndrome. Notably, we released initial positive data from our open label clinical study, representing a first for the very underserved Netherton community. That progress has continued, and based on the strength of the initial positive clinical data, we implemented a number of important protocol changes that we believe could lead to a more streamlined development program overall. “We have also strengthened our balance sheet through the recently completed $6.5 million capital raise and we have the capacity to further solidify our cash position via the $8.0 million equity line of credit transaction we entered into earlier this year, once shareholder approval is received. We continue to believe that Quoin is in position to deliver the first approved treatment for this terrible disease.” Recent Corporate Highlights – On March 4th, Quoin announced FDA Clearance to recruit teen subjects into both ongoing Netherton Syndrome clinical studies. On February 8th, 2024, Quoin filed U.S. and International patent applications for a novel Netherton Syndrome combination product. On December 13th, Quoin announced FDA clearance of the Clinical Optimization Plan for QRX003 for Netherton Syndrome On October 24th, Quoin announced positive clinical data from the first six evaluable patients in the company’s open-label clinical trial in Netherton Syndrome patients. Five of the six subjects reported that their pruritus, or itch, was either negligible or absent following treatment with QRX003, a significant improvement from prior to the study. All six subjects exhibited improvement in the Investigator assessed skin scoring system with three subjects showing improvement at the completion of the study and the other three at various points during the study. All six subjects expressed a favorable impression of QRX003 across multiple assessed metrics. No safety concerns have been reported to date for any subject in either of Quoin’s studies. Financial Highlights Quoin had approximately $10.7 million in cash, cash equivalents and marketable securities as of December 31, 2023. This does not include the proceeds from the $6.5 million public offering of common shares that the company announced on March 5, 2024, nor the anticipated proceeds from the $8 million equity line of credit transaction which was entered into in January of this year. Implementation of this remains subject to shareholder approval. Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million for the quarter ended December 31, 2022. Net loss for the twelve months ended December 31, 2023 was $8.7 million compared to $9.4 million for the twelve months ended December 31, 2022. Investors are encouraged to read the Company’s Annual Report on Form 10-K when it is filed with the Securities and Exchange Commission (the “SEC”), which will contain additional details about Quoin’s financial results as of and for the period ended December 31, 2023. Quoin will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quarter and full year 2023 financial results and a corporate update. The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international). The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link: About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: or LinkedIn for updates. Cautionary Note Regarding Forward Looking Statements The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s expected cash runway, the belief that certain protocol changes could lead to a more streamlined development program and the belief that the Company is in a position to deliver the first approved treatment for Netherton Syndrome. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 that the Company filed with the SEC. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. PCG Advisory Stephanie Prince sprince@pcgadvisory.com (646) 863-6341 -Tables Follow- QUOIN PHARMACEUTICALS LTD. Consolidated Balance Sheets December 31, December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents $ 2,401,198 $ 2,860,628 Investments 8,293,663 9,992,900 Prepaid expenses and other current assets 591,034 516,584 Total current assets 11,285,895 13,370,112 Prepaid expenses - long term 300,000 383,390 Intangible assets, net 583,334 704,561 Total assets $ 12,169,229 $ 14,458,063 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 526,523 $ 605,600 Accrued expenses 1,308,706 1,175,705 Accrued interest and financing expense 1,146,251 1,146,251 Due to officers - short term 600,000 600,000 Total current liabilities 3,581,480 3,527,556 Due to officers - long term 2,923,733 3,523,733 Total liabilities $ 6,505,213 $ 7,051,289 Commitments and contingencies Shareholders' equity: Ordinary shares, no par value per share, 100,000,000 and 8,333,334 ordinary shares authorized at December 31, 2023 and 2022, respectively - 987,220 (987,220 ADS's) $ - $ - ordinary shares issued and outstanding at December 31, 2023 and 403,887 (403,887 ADS's) at December 31, 2022 Treasury stock, - (2,932,000 ) -0- ordinary shares issued at December 31, 2023 and 45 ordinary shares issued at December 31, 2022 Additional paid in capital 51,867,336 47,855,521 Accumulated deficit (46,203,320 ) (37,516,747 ) Total shareholders' equity 5,664,016 7,406,774 Total liabilities and shareholders' equity $ 12,169,229 $ 14,458,063 QUOIN PHARMACEUTICALS LTD. Consolidated Statements of Operations Years Ended December 31, Three months ended December 31, 2023 2022 2023 2022 (Audited) (Audited) (Unaudited) (Unaudited) Operating expenses General and administrative $ 6,070,517 $ 6,584,868 $ 1,385,276 $ 1,472,866 Research and development 3,307,987 2,672,836 832,391 613,067 Total operating expenses 9,378,504 9,257,704 2,217,667 2,085,933 Other (income) and expenses Forgiveness of accounts payable - (416,000 ) - - Warrant liability (income) expense - (77,237 ) - - Unrealized loss (gain) 2,683 (1,307 ) (9,243 ) (4,360 ) Realized and accrued interest income (694,614 ) (95,745 ) (158,546 ) (80,613 ) Interest and financing expense - 714,081 - - Total other (income) expense (691,931 ) 123,792 (167,789 ) (84,973 ) Net loss $ (8,686,573 ) $ (9,381,496 ) $ (2,049,878 ) $ (2,000,960 ) Deemed dividend on warrant modification - (65,266 ) - - Net loss attributable to shareholders $ (8,686,573 ) $ (9,446,762 ) $ (2,049,878 ) $ (2,000,960 ) Loss per ADS Basic $ (9.64 ) $ (46.81 ) $ (2.08 ) $ (4.95 ) Fully-diluted $ (9.64 ) $ (46.81 ) $ (2.08 ) $ (4.95 ) Weighted average number of ADS's outstanding Basic 900,919 201,826 987,220 403,884 Fully-diluted 900,919 201,826 987,220 403,884

MADISON, N.J.--( BUSINESS WIRE )-- NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Timber Pharmaceuticals, Inc., a LEO Pharma company, today presents preliminary results from the ASCEND trial in a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting. 1 The results offer a first look at the safety, efficacy and pharmacokinetic (PK) data from 17 adult and adolescent participants (aged 12-64 years) enrolled in the open-label maximum use arm of the phase 3 ASCEND trial. 1 These late-breaker results are part of a wide-ranging data program from LEO Pharma at AAD, with eight abstracts accepted in total for the meeting, showcasing an ongoing commitment to advancing the standard of research in medical dermatology. ASCEND is a clinical trial of TMB-001, a polyethylene glycol (iPEG™) based investigational topical isotretinoin being developed for the treatment of moderate-to-severe X-linked and autosomal recessive congenital ichthyosis (CI). 3 CI is a group of rare genetic keratinization disorders that leads to dry, thickened, and scaling skin. 4-7 Currently, no specific treatments are approved by the U.S. Food and Drug Administration (FDA) to treat CI. 2 Patients enrolled in the open-label maximum use arm of the ASCEND trial with 75-90% body surface area involvement and moderate-to-severe disease on the Investigator Global Assessment (IGA) scale (IGA scores ≥3) were included in this analysis. 1 TMB-001 results showed that, from baseline to Week 12, the mean total Investigator Global Assessment (IGA) composite scaling and fissuring score decreased from 3.2 to 1.6 (p=0.0001). In the same timeframe, 59% of patients achieved a ≥2 point decrease in IGA scores from baseline, while 82% demonstrated a clinically significant (≥1 point) improvement in IGA scores from baseline. 1 No serious adverse events (SAEs) were reported. 1 65% of participants experienced at least 1 adverse event (AE), with a total of 35 events. 1 The top three treatment-emergent AEs were erythema (N=7), pruritus (N=4), and stinging/pain (N=2). 1 “ The preliminary findings from the ASCEND trial are encouraging and indicate the potential of TMB-001 to provide hope for those living with X-linked and autosomal recessive CI,” said Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma. “ We know that the management of this disease can be incredibly challenging and, given the limited treatment options available, we remain focused on pushing the development of TMB-001 forward with the goal of helping to address this considerable unmet need.” The results were taken from participants in the open-label maximal use arm of the ASCEND trial. This arm aimed to analyze the PKs of TMB-001 by determining the level of systemic exposure of isotretinoin and metabolites. 1 To do this, the change from baseline of isotretinoin (ISO), 4-oxo-isotretinoin (4-O-ISO), tretinoin (TR), and 4-oxo-tretinoin (4-O-TR) after 14 days of twice-daily application of TMB-001 was assessed. 1 The data demonstrated low systemic concentrations across all four molecules examined after 14 days of twice-daily application of TMB-001. 1 The steady-state mean peak plasma concentrations (ng/mL) in the 17 participants were 4.5 for ISO, 9.0 for 4-O-ISO, and low to not calculable for TR and 4-O-TR. 1 “ X-linked and autosomal recessive CI can be incredibly challenging to live with, and in my experience patients are often impacted both psychically and psychologically by a host of symptoms,” said Dr. Christopher Bunick, Lead Author and Associate Professor of Dermatology, Yale School of Medicine. “ With no specific treatment currently available, CI patients are currently having to deal with their condition with minimal support. I hope that the data and insights presented today can help provide new knowledge and support for this patient community.” In January 2024, LEO Pharma finalized the acquisition of Timber Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. Upon completion, the Timber Pharmaceuticals lead investigational product candidate, TMB-001, was added to LEO Pharma’s pipeline. TMB-001 is under investigation and has not been evaluated by any health authority. About the ASCEND Trial An ongoing, multicenter phase 3 study to evaluate the efficacy and safety of TMB-001 0.05% topical ointment in the treatment of congenital ichthyosis (CI) in subjects (aged ≥6 years) with either the autosomal recessive congenital ichthyosis (ARCI) or X-linked recessive ichthyosis (XLRI) subtypes. 3 The clinical trial is divided into two parts. The first is a randomized, double-blind, vehicle-controlled phase III study. Its objective is to ascertain the efficacy of TMB-001 0.05% topical ointment as a treatment for CI compared with vehicle during 12 weeks of treatment. 3 In the second part of the trial, a subset of preselected centers will recruit subjects in parallel with either the ARCI or XLRI subtypes for enrollment into an Optional Maximal Use arm. The primary objective of this part of the trial is to determine systemic exposure of isotretinoin and metabolites after single or multiple applications of TMB-001 0.005% ointment. Its primary endpoint is an assessment of individual concentrations of 4-oxo-isotretinoin (4-O-ISO), tretinoin (TR), 4-oxo-tretinoin (4-O-TR) and change from baseline. 3 About Congenital Ichthyosis Congenital ichthyosis (CI) is a group of rare genetic keratinization disorders that can lead to dry, thickened, and scaling skin. 4-7 Most cases of ichthyosis are inherited, but some types develop in association with genetic syndromes or diseases, such as Hodgkin's Lymphoma. 8,9 People living with CI may have limited range of motion, chronic itching, an inability to sweat normally, high risk of secondary infections, and impaired eyesight or hearing. 4-7 About TMB-001 TMB-001, topical isotretinoin in the company’s investigational patented polyethylene glycol (IPEG™) delivery system, is being developed for the treatment of moderate-to-severe subtypes of congenital ichthyosis (CI). During Q4 2021, the positive topline results for its Phase 2b CONTROL Study were announced. In Q1 2022, TMB-001 received both Breakthrough Therapy Designation and Fast Track Status from the U.S. Food and Drug Administration (FDA). The Phase 3 ASCEND clinical trial was initiated in Q2 2022. About LEO Pharma LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion. References Bunick CG, et al. Efficacy, Safety and Pharmacokinetics of First 17 Adult and Adolescent Subjects in Maximal Use Portion of Vehicle Controlled ASCEND Trial of Polyethylene Glycol (iPEG™)-Based Topical Isotretinoin 0.05% (TMB-001) for Treatment of Congenital Ichthyosis. Presented at American Academy of Dermatology (AAD) 2024 Annual Meeting, San Diego, Ca., March 8-12, 2024. Hernández-Martin A, Aranegui B, Martin-Santiago A, Garcia-Doval I. A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. J Am Acad Dermatol . 2013;69(4):544-549.e8. ClinicalTrials.gov. National Library of Medicine (U.S.). The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis (ASCEND). Identifier: NCT05295732. https://classic.clinicaltrials.gov/ct2/show/NCT05295732 Oji V, Traupe H. Ichthyosis: clinical manifestations and practical treatment options. Am J Clin Dermatol. 2009;10(6):351-364. Takeichi T, Akiyama M. Inherited ichthyosis: Non-syndromic forms. J Dermatol. 2016;43(3):242-251. Vahlquist A, Gånemo A, Virtanen M. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol. 2008;88(1):4-14. Lilly E, Bunick CG. Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clin Cosmet Investig Dermatol. 2023;16:2473-2479. Haber R, Feghali J, Nadir U, Yi MD, Cahn BA. Acquired ichthyosis: a clinical review. Arch Dermatol Res. 2023;315(9):2529-2543. Mishra K, Jandial A, Gupta K, Prakash G, Malhotra P. Ichthyosis: A Harbinger of Lymphoma. BMJ Case Rep. 2018;2018:bcr2018224229. MAT-71602 March 2024